Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 46

1.

How to predict the risk of fracture in HIV?

Yin MT, Falutz J.

Curr Opin HIV AIDS. 2016 May;11(3):261-7. doi: 10.1097/COH.0000000000000273.

PMID:
26918651
2.

More than osteoporosis: age-specific issues in bone health.

Erlandson KM, Guaraldi G, Falutz J.

Curr Opin HIV AIDS. 2016 May;11(3):343-50. doi: 10.1097/COH.0000000000000258.

PMID:
26882460
3.

HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls.

Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, Prins M, Falutz J, Reiss P; AGEhIV Cohort Study Group.

AIDS. 2016 Jan;30(2):241-50. doi: 10.1097/QAD.0000000000000910.

PMID:
26684821
4.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.

5.

A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity.

Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, Santoro A, Menozzi M, Mussi C, Mussini C, Kirkland S, Falutz J, Rockwood K.

AIDS. 2015 Aug 24;29(13):1633-41. doi: 10.1097/QAD.0000000000000753.

PMID:
26372273
6.

Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis.

Falutz J.

Clin Infect Dis. 2015 Aug 15;61(4):581-3. doi: 10.1093/cid/civ329. Epub 2015 Apr 23. No abstract available.

PMID:
25908681
7.

Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles.

Guaraldi G, Zona S, Brothers TD, Carli F, Stentarelli C, Dolci G, Santoro A, Beghetto B, Menozzi M, Mussini C, Falutz J.

PLoS One. 2015 Apr 13;10(4):e0118531. doi: 10.1371/journal.pone.0118531. eCollection 2015.

8.

Frailty in people aging with human immunodeficiency virus (HIV) infection.

Brothers TD, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston BL, Rockwood K.

J Infect Dis. 2014 Oct 15;210(8):1170-9. doi: 10.1093/infdis/jiu258. Epub 2014 Jun 5.

9.

Aging and HIV: an evolving understanding.

Justice A, Falutz J.

Curr Opin HIV AIDS. 2014 Jul;9(4):291-3. doi: 10.1097/COH.0000000000000081. No abstract available.

10.

Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.

Ndumbi P, Falutz J, Pant Pai N, Tsoukas CM.

PLoS One. 2014 Apr 7;9(4):e94018. doi: 10.1371/journal.pone.0094018. eCollection 2014.

11.

Surrogate markers of visceral adipose tissue in treated HIV-infected patients: accuracy of waist circumference determination.

Falutz J, Rosenthall L, Kotler D, Zona S, Guaraldi G.

HIV Med. 2014 Feb;15(2):98-107. doi: 10.1111/hiv.12085. Epub 2013 Sep 22.

12.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.

13.

Management of fat accumulation in patients with HIV infection.

Falutz J.

Curr HIV/AIDS Rep. 2011 Sep;8(3):200-8. doi: 10.1007/s11904-011-0087-3. Review. Erratum in: Curr HIV/AIDS Rep. 2011 Dec;8(4):297-9.

PMID:
21739217
14.

Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.

Falutz J.

Drugs Today (Barc). 2011 Jun;47(6):419-30. doi: 10.1358/dot.2011.47.6.1603439.

PMID:
21695284
15.

Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.

Falutz J.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):517-29. doi: 10.1016/j.beem.2010.11.001. Review.

PMID:
21663844
16.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.

17.

HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies.

Falutz J.

Curr Opin Clin Nutr Metab Care. 2011 May;14(3):255-60. doi: 10.1097/MCO.0b013e3283457a8f. Review.

PMID:
21460720
18.

Estimation of total-body and regional soft tissue composition from DXA bone densitometry of the lumbar spine and hip.

Rosenthall L, Falutz J.

J Clin Densitom. 2010 Jul-Sep;13(3):263-6. doi: 10.1016/j.jocd.2010.05.001.

PMID:
20670882
19.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.

PMID:
20554713
20.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.

PMID:
20101189
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk